This excellent therapeutic efficacy was likely due to several reasons, such as the good bone targeting ability of the ALN-modified NPs, the effective cancer cell killing effects of the (DTXL + siRNA)@NPs-ALN, and the osteoclast functions inhibition and osteoblast functions promotion, etc. The CaP NPs exhibited good biocompatibility, and this study also found by H&E staining that the major organs of the mice which were administered with NPs did not have damage. Here, ARLN is linked to cancer.